Business Wire

ECT

31.1.2020 10:32:09 CET | Business Wire | Press release

Share
ECT Defies Market Trends, Making 2019 a Landmark Year

ECT (European Computer Telecoms AG), Europe’s leading communications software company for the realization of value-added services, announces that the company again achieved record growth in 2019. The company experienced an annual order intake of over 23 million EUR. Although the company’s audited, consolidated annual report has yet be completed, it is already clear that in 2019 ECT exceeded the 20% top-line growth achieved in the previous year, while the bottom line grew by over 30%. In addition, due to the high order backlog at the close of 2019 and maintenance contracts for 2020, ECT already has more than 12 million EUR on its books for this year and anticipates continued record growth.

This landmark development is in line with the Board’s long-term goal of maintaining at least 20% year-to-year revenue growth. As Marshall E. Kavesh, the CEO and cofounder of ECT, explains, “after more than 20 years as a profitable, but midsized market player, we last year took on the ambitious goal of growing ECT from a 20 million Euro to a 100 million Euro company by no later than 2025. With the excellent results of the last two years we have made important steps in this direction. Our continued growth, profitability, customer relationships and innovations are the foundation for the long-term prosperity and independence of our company. This is a commitment we make to all the colleagues in our fantastic ECT team and especially to our much appreciated customers.”

Key highlights for 2019 include:

Expanded Depth and Breadth of Customer Relationships

- The vast majority of the orders were received from first-tier carriers which have been ECT customers for 10 years and longer, attesting to the deep satisfaction of the company’s customer base.

- In addition, the company, whose roots are in Europe, continued to expand its footprint in the Americas with new customer acquisitions and conducted direct sales worldwide.

- With one of Finland’s leading telecommunications operators, DNA, the company closed a three-year contract worth many millions of euros for the provision of, amongst other things, licenses for ECT’s application for Virtual PBX / Unified Communications, a license for the Service Creation Environment of the company’s Telephony Application Server (TAS) as well as the utilization of a Dedicated Agile Programming Squad .

- In indirect sales via its partner Nokia Software, the company took part in tenders worldwide, e.g. closing yet another major multimillion deal.

Major Investments in Cutting-Edge Telecoms Technology

- The company founded a new R&D unit for NFVi architecture, implemented integration with Nokia’s CloudBand Application Manager (CBAM) and plans to continue certification with other major VNF Managers in 2020. Few competitors are capable of offering this important, cost-reducing technology.

- All new solutions are implemented based on ECT’s VNFs with the option of full integration with a third-party VNF Manager, providing Automated Lifecycle Management.

- ECT implemented agile methodology throughout the company starting in January 2019 and also launched a program allowing CSPs to take under contract an ECT Dedicated Agile Programming Squad, enabling them to respond in extremely short cycles to the customizations and enhancements demanded by their major corporate and municipal customers.

- Within the framework of ECT’s Joint Agile Product Development, the company’s Innovation Department successfully launched its cutting-edge application for unified communications and collaboration, ECT Workspace, with selected CSPs.

Rapid Organization Growth

- Although many other telecoms vendors are in retrenchment, ECT is accelerating the growth of its team: In 2019, the number of employees increased by ca. 25% compared to 2018 and is expected to grow by at least another 25% by the end of this year, the majority of the new positions being in R&D.

About ECT (European Computer Telecoms AG):

For more information about ECT, please visit our website: www.ect-telecoms.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye